BIOTRON Profile

Performance

   

Odds of Distress

Check how we calculate scores
Equity ratings for BIOTRON are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting July 22, 2019 and ending today October 20, 2019. Click here to learn more.

BIOTRON Profile

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including Dengue, Zika, Influenza, Ebola, and SARs. BIOTRON operates under Biotechnology classification in USA and is traded on BATS Exchange. more
NameBIOTRON
CEOMichelle MillerView All
Macroaxis Advice
InstrumentUSA OTC Stock View All
Business Address56 Delhi Road
ExchangeBATS Exchange
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.biotron.com.au
Phone61 2 9805 0488
CurrencyUSD - US Dollar
Next Fiscal Year EndJune 30, 2021
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndJune 30, 2019
BIOTRON [BITRF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with current market capitalization of 29.55 M. BIOTRON classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 595.71 M outstanding shares. BIOTRON LTD has accumulated about 1.14 M in cash with (1.36 M) of positive cash flow from operations.
Check BIOTRON Probability Of Bankruptcy

BIOTRON Target Price Odds Analysis

Odds Below 0.052HorizonTargetOdds Above 0.052
27.24%30 days 0.05 72.68%
Based on normal probability distribution, the odds of BIOTRON to move above current price in 30 days from now is about 72.68 (This BIOTRON probability density function shows the probability of BIOTRON OTC Stock to fall within a particular range of prices over 30 days) .

BIOTRON Risk Profiles

BIOTRON Key Fundamentals

BIOTRON Against Markets

Did you try this?

Run Portfolio Reporting Now

   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
All  Next Launch Module

BIOTRON Corporate Directors

Robert Thomas Independent Non-Executive Director
Stephen Locarnini Director
Denis Wade Independent Non-Executive Director
Check also Trending Equities. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.
Search macroaxis.com